

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/571,991
				Filing Date	March 15, 2006
				First Named Inventor	Hennequin
				Art Unit	1624
				Examiner Name	Douglas M. WILLIS
Sheet	1	of	2	Attorney Docket Number	09963.0008-00000

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No.	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation
		Country Code Number Kind Code (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation
	1	<i>In re Hilmer</i> , 359 F.2d 859, 149 USPQ 480 (CCPA 1966)	
	2	<i>In re Deckler</i> , 977 F.2d 1449, 24 USPQ2d 1448 (Fed. Cir. 1992)	
	3	<i>Ex parte Tytgat</i> , 225 USPQ 907 (Bd. Pat. App. & Inter. 1985)	
	4	37 CFR §41.127(a)(1)	
	5	<i>Ex parte Kimura</i> , 55 USPQ2d 1537 (Bd. Pat. App. & Inter. 2000)	
	6	<i>Ex parte A</i> , 17 USPQ2d 1716 (Bd. Pat. App. & Inter. 1990)	
	7	<i>Net Money/IN, Inc. v. Verisign, Inc.</i> , 545 F.3d 1359 (Fed. Cir. 2008)	
	8	<i>Eisai Co. Ltd. v. Teva Pharmaceuticals USA, Inc.</i> , 533 F.3d 1353 (Fed. Cir. 2008)	
	9	<i>In re Baird</i> , 16 F.3d 380, 382, 29 USPQ2d 1550 (Fed. Cir. 1994)	
	10	<i>In re Jones</i> , 958 F.2d 347 (Fed. Cir. 1992)	
	11	<i>Takeda Chemical Industries, Ltd. V. Alphapharm Pty., Ltd.</i> , 492 F.3d 1350 (Fed. Cir. 2007)	
	12	<i>In re Deuel</i> , 51 F.3d 1552 (Fed. Cir. 1995)	
	13	Pages from Federal Register's Notice of Proposed Rulemaking, 49 FR 3768, dated January 30, 1984	
	14	<i>Tafas v. Doll</i> , slip op. (Fed. Cir. March 20, 2009)	
	15	<i>In re Wilding</i> , 535 F.2d 631 (1976, CCPA)	

Examiner Signature	/Douglas Willis/	Date Considered	11/19/2009
-----------------------	------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.W./

Sheet

2

of

2

Application Number

10/571.991

Filing Date

March 15, 2006

First Named Inventor

Hennequin

Art Unit

1624

Examiner Name

Douglas M. WILLIS

Attorney Docket Number

09963.0008-00000

Examiner
InitialsCite
No.

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

Translation

16

In re Kaplan, 789 F.2d 1574 (Fed. Cir. 1986)

17

In re Sarrett, 327 F.2d 1005, (CGPA 1964)

18

The Procter & Gamble Company v. Teva Pharmaceuticals USA, Inc., ___ F.3d ___, No. 2008-1404, -1405, -1406 (Fed. Cir. May 13, 2009)

19

In re Kubin, ___ F.3d ___, No. 2008-1184, (Fed. Cir. Apr. 3, 2009)

Examiner
Signature

/Douglas Willis/

Date
Considered

11/19/2009

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.W./